Experimental therapies and ongoing clinical trials to slow down progression of ADPKD

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

The improvement of imaging techniques over the years has contributed to the understanding of the natural history of autosomal dominant polycystic kidney disease, and facilitated the observation of its structural progression. Advances in molecular biology and genetics have made possible a greater understanding of the genetics, molecular, and cellular pathophysiologic mechanisms responsible for its development and have laid the foundation for the development of potential new therapies. Therapies targeting genetic mechanisms in ADPKD have inherent limitations. As a result, most experimental therapies at the present time are aimed at delaying the growth of the cysts and associated interstitial inflammation and fibrosis by targeting tubular epithelial cell proliferation and fluid secretion by the cystic epithelium. Several interventions affecting many of the signaling pathways disrupted in ADPKD have been effective in animal models and some are currently being tested in clinical trials.

Original languageEnglish (US)
Pages (from-to)44-59
Number of pages16
JournalCurrent Hypertension Reviews
Volume9
Issue number1
StatePublished - 2013

Fingerprint

Autosomal Dominant Polycystic Kidney
Investigational Therapies
Molecular Biology
Clinical Trials
Fluids and Secretions
Genetic Therapy
Cysts
Fibrosis
Epithelium
Animal Models
Epithelial Cells
Cell Proliferation
Observation
Inflammation
Growth
Therapeutics

Keywords

  • AMP-activated protein kinase (AMPK) activators
  • Autosomal dominant polycystic kidney disease
  • Cystic fibrosis transmembrane conductance regulator (CFTR) inhibitors
  • Mammalian target of rapamycin (mTOR) inhibitors
  • Somatostatin analogues
  • Src inhibitors

ASJC Scopus subject areas

  • Internal Medicine

Cite this

@article{db589c2cfd1e4855b507d005da31d2cd,
title = "Experimental therapies and ongoing clinical trials to slow down progression of ADPKD",
abstract = "The improvement of imaging techniques over the years has contributed to the understanding of the natural history of autosomal dominant polycystic kidney disease, and facilitated the observation of its structural progression. Advances in molecular biology and genetics have made possible a greater understanding of the genetics, molecular, and cellular pathophysiologic mechanisms responsible for its development and have laid the foundation for the development of potential new therapies. Therapies targeting genetic mechanisms in ADPKD have inherent limitations. As a result, most experimental therapies at the present time are aimed at delaying the growth of the cysts and associated interstitial inflammation and fibrosis by targeting tubular epithelial cell proliferation and fluid secretion by the cystic epithelium. Several interventions affecting many of the signaling pathways disrupted in ADPKD have been effective in animal models and some are currently being tested in clinical trials.",
keywords = "AMP-activated protein kinase (AMPK) activators, Autosomal dominant polycystic kidney disease, Cystic fibrosis transmembrane conductance regulator (CFTR) inhibitors, Mammalian target of rapamycin (mTOR) inhibitors, Somatostatin analogues, Src inhibitors",
author = "{Irazabal Mira}, Maria and Vicente Torres",
year = "2013",
language = "English (US)",
volume = "9",
pages = "44--59",
journal = "Current Medical Imaging Reviews",
issn = "1573-4056",
publisher = "Bentham Science Publishers B.V.",
number = "1",

}

TY - JOUR

T1 - Experimental therapies and ongoing clinical trials to slow down progression of ADPKD

AU - Irazabal Mira, Maria

AU - Torres, Vicente

PY - 2013

Y1 - 2013

N2 - The improvement of imaging techniques over the years has contributed to the understanding of the natural history of autosomal dominant polycystic kidney disease, and facilitated the observation of its structural progression. Advances in molecular biology and genetics have made possible a greater understanding of the genetics, molecular, and cellular pathophysiologic mechanisms responsible for its development and have laid the foundation for the development of potential new therapies. Therapies targeting genetic mechanisms in ADPKD have inherent limitations. As a result, most experimental therapies at the present time are aimed at delaying the growth of the cysts and associated interstitial inflammation and fibrosis by targeting tubular epithelial cell proliferation and fluid secretion by the cystic epithelium. Several interventions affecting many of the signaling pathways disrupted in ADPKD have been effective in animal models and some are currently being tested in clinical trials.

AB - The improvement of imaging techniques over the years has contributed to the understanding of the natural history of autosomal dominant polycystic kidney disease, and facilitated the observation of its structural progression. Advances in molecular biology and genetics have made possible a greater understanding of the genetics, molecular, and cellular pathophysiologic mechanisms responsible for its development and have laid the foundation for the development of potential new therapies. Therapies targeting genetic mechanisms in ADPKD have inherent limitations. As a result, most experimental therapies at the present time are aimed at delaying the growth of the cysts and associated interstitial inflammation and fibrosis by targeting tubular epithelial cell proliferation and fluid secretion by the cystic epithelium. Several interventions affecting many of the signaling pathways disrupted in ADPKD have been effective in animal models and some are currently being tested in clinical trials.

KW - AMP-activated protein kinase (AMPK) activators

KW - Autosomal dominant polycystic kidney disease

KW - Cystic fibrosis transmembrane conductance regulator (CFTR) inhibitors

KW - Mammalian target of rapamycin (mTOR) inhibitors

KW - Somatostatin analogues

KW - Src inhibitors

UR - http://www.scopus.com/inward/record.url?scp=84875333002&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84875333002&partnerID=8YFLogxK

M3 - Article

C2 - 23971644

AN - SCOPUS:84875333002

VL - 9

SP - 44

EP - 59

JO - Current Medical Imaging Reviews

JF - Current Medical Imaging Reviews

SN - 1573-4056

IS - 1

ER -